---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039445"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:29:58.693271+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus presents Phase 1 Decoy20 interim data: stable disease in all 4 patients

## Summary
- All four patients in first cohort showed stable disease at 4 weeks; three had progressive disease at baseline.
- Decoy20 induced transient expression of over 50 biomarkers associated with innate/adaptive anti-tumor immune responses.
- Adverse events generally tolerable, resolved within 30 minutes to 3 days; drug cleared from blood in 30-120 minutes.
- Peak cytokine/chemokine induction ~4-24 hours, returning to baseline by 24-48 hours, avoiding prolonged toxicity.

## SEC filing metadata
- accession: 0001493152-23-039445
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223039445/0001493152-23-039445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223039445/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039445
- JSON: https://secwatch.observer/filing/0001493152-23-039445.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.